Lexaria Bioscience Corp (LEXX)
3.28
+0.21 (+6.84%)
USD |
NASDAQ |
Jun 24, 16:00
3.28
0.00 (0.00%)
After-Hours: 18:19
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 19.52M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -53.77% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 64.92 |
Price to Book Value | 1.704 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.0007 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 97.33% |
News
Headline
Wire
Time (ET)
SA Breaking News
06/21 10:24
SA Breaking News
06/21 10:03
SA Breaking News
06/08 10:13
MT Newswires
06/03 04:17
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
07/15/2022* | -- | Results | Q3 2022 | -- | -0.28 | -- | |
01/14/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
11/29/2021 | -- | Results | Q4 2021 | -- | -- | -- | |
07/15/2021 | -- | Results | Q3 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio. |
URL | https://www.lexariabioscience.com |
Investor Relations URL | http://www.lexariaenergy.com/investors/ |
HQ State/Province | British Columbia |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | Jul. 15, 2022 (est.) |
Last Earnings Release | Jan. 14, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of June 23, 2022.
Fundamentals
Revenue (TTM) | 0.2796M |
Total Expenses (TTM) | 7.657M |
Net Income (TTM) | -7.154M |
Total Assets (Quarterly) | 11.41M |
Total Liabilities (Quarterly) | 0.1946M |
Shareholders Equity (Quarterly) | 11.46M |
Cash from Operations (TTM) | -4.712M |
Cash from Investing (TTM) | -0.1634M |
Cash from Financing (TTM) | 3.971M |
Ratings
Profile
Edit
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio. |
URL | https://www.lexariabioscience.com |
Investor Relations URL | http://www.lexariaenergy.com/investors/ |
HQ State/Province | British Columbia |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | Jul. 15, 2022 (est.) |
Last Earnings Release | Jan. 14, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Morningstar | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
LEXX Tweets |